#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    B-cell lymphoma recurrent Extra-osseous Ewing's sarcoma recurrent Juvenile chronic myelomonocytic leukaemia Angiosarcoma recurrent Chordoma Subdural haematoma Tuberous sclerosis complex Cholangitis sclerosing Inborn error of metabolism Hypochondroplasia Emphysema Ichthyosis Ureteric cancer Myocarditis Salivary gland cancer More trials…

    Learn about Rare Diseases

    Castleman’s disease Haemophilia A without inhibitors – Basic Information Chondrosarcoma metastatic – Life with Disease Alport’s syndrome – Life with Disease Medulloblastoma – Treatment Atypical haemolytic uraemic syndrome – Treatment Progressive supranuclear palsy Methylmalonic acidaemia – Treatment Langerhans’ cell histiocytosis Prolymphocytic leukaemia – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Baclofen Ly3819469 Sodium Mk-1942 Sirolimus RIKKUNSHITO GLYCYL-TYROSINE Hmb-001 Agrostis Stolonifera Pollen Ly3473329 Palbociclib Corline Heparin Conjugate Ads-010 Amlitelimab Cldn6 Car-T TORASEMIDE Metyrapone Bp Oxazepam Dapagliflozin Bedaquiline Prasugrel Hydrobromide More therapies…

    Learn about Your Condition

    Myotonic dystrophy Spondylolisthesis Endometrial cancer stage IV Onychomycosis Combined immunodeficiency Malignant melanoma stage II Skin ulcer Vomiting Ewing's sarcoma recurrent Naevoid melanoma Yellow fever Diabetic gastroparesis Sleep disorder Lymphocytic leukaemia Brain neoplasm More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Human papilloma virus immunisation

  • A study on the long-term effectiveness and safety of nine-valent human papillomavirus vaccine in women aged 16 to 26 years for prevention of cervical cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Human Papillomavirus Type 11 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
    • Human Papillomavirus Type 16 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
    • Human Papillomavirus Type 18 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
    Denmark Norway Sweden

  • Study on the Effectiveness of the Nonavalent HPV Vaccine in Treating Hard-to-Treat Palmar or Plantar Warts in Patients Who Have Not Responded to Two Previous Treatments

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Human Papillomavirus Type 11 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
    • Human Papillomavirus Type 16 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
    • Human Papillomavirus Type 18 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
    France

  • Study on HPV Vaccine for Women with Vulvar HSIL: Evaluating the Effectiveness of Nonavalent HPV Vaccine in Preventing Recurrence of Vulvar High-Grade Lesions

    Recruiting

    3 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of the vulva
    Investigated Drugs:
    • Human Papillomavirus Type 11 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
    • Human Papillomavirus Type 16 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
    • Human Papillomavirus Type 18 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
    The Netherlands

  • Study on the Safety and Immune Response of 9vHPV Vaccine in Preventing HPV in Boys and Girls Aged 9-14 Compared to Young Women Aged 16-26

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Human Papillomavirus Type 11 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
    • Human Papillomavirus Type 16 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
    • Human Papillomavirus Type 18 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
    Poland

  • Study on the Effectiveness of the 9-Valent HPV Vaccine in Children and Adolescents with Weakened Immune Systems

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Human Papillomavirus Type 11 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
    • Human Papillomavirus Type 16 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
    • Human Papillomavirus Type 18 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
    Spain

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!